342 related articles for article (PubMed ID: 30941558)
1. What uro-gynecologists should know about sacral neuromodulation (SNM) for the treatment of refractory overactive bladder.
Oelke M; Addali M; Reisenauer C
Arch Gynecol Obstet; 2019 May; 299(5):1243-1252. PubMed ID: 30941558
[TBL] [Abstract][Full Text] [Related]
2. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
Hoag N; Plagakis S; Pillay S; Edwards AW; Gani J
Neurourol Urodyn; 2017 Jun; 36(5):1377-1381. PubMed ID: 27612039
[TBL] [Abstract][Full Text] [Related]
3. Sacral neuromodulation in patients with refractory overactive bladder symptoms after failed Botulinum toxin therapy: Results in a large cohort of patients.
Reekmans M; Janssen JMW; Vrijens DMJ; Smits MAC; van Koeveringe GA; Van Kerrebroeck PEVA
Neurourol Urodyn; 2021 Jun; 40(5):1120-1125. PubMed ID: 33829519
[TBL] [Abstract][Full Text] [Related]
4. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Urinary Urgency Incontinence Using a Rechargeable SNM System: 6-Month Results of the ARTISAN-SNM Study.
McCrery R; Lane F; Benson K; Taylor C; Padron O; Blok B; De Wachter S; Pezzella A; Gruenenfelder J; Pakzad M; Perrouin-Verbe MA; Le Normand L; Van Kerrebroeck P; Mangel J; Peters K; Kennelly M; Shapiro A; Lee U; Comiter C; Mueller M; Goldman HB
J Urol; 2020 Jan; 203(1):185-192. PubMed ID: 31347955
[TBL] [Abstract][Full Text] [Related]
6. Sacral neuromodulation and intravesical botulinum toxin for refractory overactive bladder.
Kantartzis K; Shepherd J
Curr Opin Obstet Gynecol; 2012 Oct; 24(5):331-6. PubMed ID: 22922403
[TBL] [Abstract][Full Text] [Related]
7. A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study.
Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe MA; Elneil S
Neurourol Urodyn; 2019 Feb; 38(2):689-695. PubMed ID: 30592526
[TBL] [Abstract][Full Text] [Related]
8. [Sacral neuromodulation in under- and overactive detrusor-quo vadis? : Principles and developments].
Girtner F; Burger M; Mayr R
Urologe A; 2019 Jun; 58(6):634-639. PubMed ID: 31139864
[TBL] [Abstract][Full Text] [Related]
9. Medium-term outcomes of sacral neuromodulation in patients with refractory overactive bladder: A retrospective single-institution study.
Kaaki B; Gupta D
PLoS One; 2020; 15(7):e0235961. PubMed ID: 32645082
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Two Treatment Modalities in Overactive Bladder: A Rapid Overview.
Mirza AA; Alamoudi MA; Mirza AA; Alsubaie MA; Abuzenada MA
Med Arch; 2022 Dec; 76(6):469-472. PubMed ID: 36937615
[TBL] [Abstract][Full Text] [Related]
11. Sacral neuromodulation for the treatment of overactive bladder: systematic review and future prospects.
Tilborghs S; De Wachter S
Expert Rev Med Devices; 2022 Feb; 19(2):161-187. PubMed ID: 35061951
[TBL] [Abstract][Full Text] [Related]
12. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder.
Siegel S; Noblett K; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Berg KC; Kan F; Irwin CP
Neurourol Urodyn; 2015 Mar; 34(3):224-30. PubMed ID: 24415559
[TBL] [Abstract][Full Text] [Related]
13. The role of neuromodulation in patients with neurogenic overactive bladder.
Lay AH; Das AK
Curr Urol Rep; 2012 Oct; 13(5):343-7. PubMed ID: 22865208
[TBL] [Abstract][Full Text] [Related]
14. Refractory overactive bladder patients who chose sacral neuromodulation therapy after failed OnabotulinumtoxinA treatment: A systematic review and meta-analysis.
Yang G; Xu Y; Qu G; Zhang Y
PLoS One; 2020; 15(3):e0230355. PubMed ID: 32226049
[TBL] [Abstract][Full Text] [Related]
15. Sacral neuromodulation for female pelvic floor disorders.
El-Azab AS; Siegel SW
Arab J Urol; 2019 Mar; 17(1):14-22. PubMed ID: 31258941
[No Abstract] [Full Text] [Related]
16. Impact of Overactive Bladder-Wet Syndrome on Female Sexual Function: A Systematic Review and Meta-Analysis.
Balzarro M; Rubilotta E; Mancini V; Trabacchin N; Oppezzi L; Li Marzi V; Fusco F; Serati M
Sex Med Rev; 2019 Oct; 7(4):565-574. PubMed ID: 31326358
[TBL] [Abstract][Full Text] [Related]
17. Remotely programmed sacral neuromodulation for the treatment of patients with refractory overactive bladder: a prospective randomized controlled trial evaluating the safety and efficacy of a novel sacral neuromodulation device.
Zhang Y; Zhang P; Tian X; Chen G; Li Y; Zhang Y; Xu Z; Wei Z; Zhang W; Ma L; Shi B; Liao L; Wang J
World J Urol; 2019 Nov; 37(11):2481-2492. PubMed ID: 30809700
[TBL] [Abstract][Full Text] [Related]
18. [Sacral neuromodulation for refractory overactive bladder].
van Ophoven A
Urologe A; 2018 Nov; 57(11):1375-1388. PubMed ID: 30310935
[TBL] [Abstract][Full Text] [Related]
19. [Functional results and satisfaction in 44 patients after implantation of a NS3-type sacral neurostimulator for refractory idiopathic overactive bladder followed at 43 months, single-center series].
Msika J; Kalantan M; Larre S; Leon P
Prog Urol; 2021 Oct; 31(12):725-731. PubMed ID: 33962849
[TBL] [Abstract][Full Text] [Related]
20. Trends and Clinical Practice Patterns of Sacral Neuromodulation for Overactive Bladder.
Elterman DS; Chughtai B; Vertosick E; Thomas D; Eastham J; Sandhu J
Female Pelvic Med Reconstr Surg; 2018; 24(4):264-266. PubMed ID: 28658001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]